Contributor
Neil Grubert, Juliette Sinclair-Spence, Sandrine Ruiz, Seema Sondhi
Menu
Neil Grubert, Juliette Sinclair-Spence, Sandrine Ruiz, Seema Sondhi
Welcome to this month’s episode of Letβs Talk Rare: The Life Science Podcast brought to you by Partners4Access. Host Georgie records this episode at the World EPA Conference in Amsterdam. She holds a panel discussion with Juliette Sinclair-Spence, Sandrine Ruiz,Β Neil Grubert, and Seema Sondhi, and together we shared our experiences at the EPA conference.
We also shared our excitement for AI and patient experience topics, as well as the importance of sustainability and finding new pricing approaches in healthcare. Gain insights on inclusivity and involving patients in drug development. Get ready for a meaningful, engaging conversation that will leave you inspired.
Take a deep dive into the benefits of tiered pricing, the challenges and concerns of companies and HTA agencies in joint HTA assessments, the importance of inclusivity, and the importance of involving and educating others.
Juliette is the Funder and Chairman of the AK Eye Foundation and is a committed ππππ§ππ‘ππ¦π¨πππ πππ«πππ’ππ’π¬ (ππ) ππππ’ππ§π πππ―π¨ππππ. She has experienced this rare eye disease, and her key learning was that there is much that needs to be done on many fronts, including prevention, education, diagnosis, treatment, research, and support. Her passion for fighting against the disease led her to set up the first worldwide foundation focused on Acanthamoeba Keratitis.
βI think involving patients in the drug development process is so important. We need to hear their voices and understand their journeys.β
Sandrine, or Sandy as she likes to be called, is the Senior Director of Market Access, Pricing, and HEOR at Immunocore. She is an experienced Pricing & Market Access professional with 25+ years in the biopharmaceutical industry. She has hands-on experience in giving strategic and science-based input across the pharmaceutical development workflow, from early stage to late stage, into Market/Patient Access, Pricing & Reimbursement, Payer Strategy, Real World Evidence, Clinical Development, Clinical Operations, and Business Development.
βI was really intrigued by the panel discussion on tiered pricing. It’s such a hot topic right now, and it was interesting to hear the different perspectives on patient access. I’m also fascinated by digital information and the new trends in our field.β
Neil is an Independent Global Market Access Consultant and a multilingual pharmaceutical market access specialist with 30 years of experience tracking the global prescription drug and self-medication markets. He has spearheaded the establishment and growth of Decision Resourcesβ international market access business. As the author of more than 150 reports covering 20 mature and emerging markets, multiple therapeutic areas, and numerous industry issues, he has earned a reputation for extensive knowledge of market access environments around the world.
βYes, tiered pricing is definitely a challenging issue. Speaking of challenges, the EU HTA implementation has been causing many uncertainties for companies and HTA agencies. We need to navigate it carefully.β
Seema is the Head of Payer Value and Access for the Vaccine Business Unit at Takeda. She is passionate about patient access to innovative medicines and has worked diligently in her country, regional, and global roles to ensure access to pharmaceuticals, vaccines, medical devices, and orphan drugs. This has been achieved through key activities such as influencing global clinical trial development to ensure the collection of appropriate evidence, all the way through to launching products at prices that allow good levels of patient access and ensuring continued access post-launch via mechanisms such as innovative access schemes.
βInclusivity is such an important aspect of our work. We can’t just think about it; we have to be involved and educate others actively. Patients need to understand the questions asked and the impact of their input.β
